Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 131

1.

Intravenous adeno-associated virus serotype 8 encoding urocortin-2 provides sustained augmentation of left ventricular function in mice.

Gao MH, Lai NC, Miyanohara A, Schilling JM, Suarez J, Tang T, Guo T, Tang R, Parikh J, Giamouridis D, Dillmann WH, Patel HH, Roth DM, Dalton ND, Hammond HK.

Hum Gene Ther. 2013 Sep;24(9):777-85. doi: 10.1089/hum.2013.088.

2.

Intravenous AAV8 Encoding Urocortin-2 Increases Function of the Failing Heart in Mice.

Lai NC, Gao MH, Giamouridis D, Suarez J, Miyanohara A, Parikh J, Hightower S, Guo T, Dillmann W, Kim YC, Diaz-Juarez J, Hammond HK.

Hum Gene Ther. 2015 Jun;26(6):347-56. doi: 10.1089/hum.2014.157. Epub 2015 Apr 9.

3.

The effects of vasoactive peptide urocortin 2 on hemodynamics in spontaneous hypertensive rat and the role of L-type calcium channel and CRFR2.

Liu C, Liu X, Yang J, Duan Y, Yao H, Li F, Zhang X.

Pharmacol Rep. 2015 Apr;67(2):394-8. doi: 10.1016/j.pharep.2014.10.017. Epub 2014 Nov 12.

PMID:
25712670
4.

Immunosuppression decreases inflammation and increases AAV6-hSERCA2a-mediated SERCA2a expression.

Zhu X, McTiernan CF, Rajagopalan N, Shah H, Fischer D, Toyoda Y, Letts D, Bortinger J, Gibson G, Xiang W, McCurry K, Mathier M, Glorioso JC, London B.

Hum Gene Ther. 2012 Jul;23(7):722-32. doi: 10.1089/hum.2011.108. Epub 2012 Jul 11.

5.

[Adeno-associated viral gene transfer of SERCA2a improves heart function in chronic congestive heart failure rats].

Hui HP, Li XY, Liu XH, Sun S, Lu XC, Liu T, Yang W.

Zhonghua Xin Xue Guan Bing Za Zhi. 2006 Apr;34(4):357-62. Chinese.

PMID:
16776934
6.

Reversal of cardiac dysfunction after long-term expression of SERCA2a by gene transfer in a pre-clinical model of heart failure.

Kawase Y, Ly HQ, Prunier F, Lebeche D, Shi Y, Jin H, Hadri L, Yoneyama R, Hoshino K, Takewa Y, Sakata S, Peluso R, Zsebo K, Gwathmey JK, Tardif JC, Tanguay JF, Hajjar RJ.

J Am Coll Cardiol. 2008 Mar 18;51(11):1112-9. doi: 10.1016/j.jacc.2007.12.014.

7.

Estrogens downregulate urocortin 2 expression in rat uterus.

Watanabe K, Nemoto T, Akira S, Takeshita T, Shibasaki T.

J Endocrinol. 2013 Nov 6;219(3):269-78. doi: 10.1530/JOE-13-0228. Print 2013 Dec.

8.

One-time injection of AAV8 encoding urocortin 2 provides long-term resolution of insulin resistance.

Gao MH, Giamouridis D, Lai NC, Walenta E, Paschoal VA, Kim YC, Miyanohara A, Guo T, Liao M, Liu L, Tan Z, Ciaraldi TP, Schenk S, Bhargava A, Oh DY, Hammond HK.

JCI Insight. 2016 Sep 22;1(15):e88322.

9.

Urocortin 2 stimulates nitric oxide production in ventricular myocytes via Akt- and PKA-mediated phosphorylation of eNOS at serine 1177.

Walther S, Pluteanu F, Renz S, Nikonova Y, Maxwell JT, Yang LZ, Schmidt K, Edwards JN, Wakula P, Groschner K, Maier LS, Spiess J, Blatter LA, Pieske B, Kockskämper J.

Am J Physiol Heart Circ Physiol. 2014 Sep 1;307(5):H689-700. doi: 10.1152/ajpheart.00694.2013. Epub 2014 Jul 11.

10.

Improved function of the failing rat heart by regulated expression of insulin-like growth factor I via intramuscular gene transfer.

Lai NC, Tang T, Gao MH, Saito M, Miyanohara A, Hammond HK.

Hum Gene Ther. 2012 Mar;23(3):255-61. doi: 10.1089/hum.2011.094. Epub 2012 Jan 12.

11.

Urocortin 2 autocrine/paracrine and pharmacologic effects to activate AMP-activated protein kinase in the heart.

Li J, Qi D, Cheng H, Hu X, Miller EJ, Wu X, Russell KS, Mikush N, Zhang J, Xiao L, Sherwin RS, Young LH.

Proc Natl Acad Sci U S A. 2013 Oct 1;110(40):16133-8. doi: 10.1073/pnas.1312775110. Epub 2013 Sep 16.

12.

Augmentation of left ventricular mechanics by recirculation-mediated AAV2/1-SERCA2a gene delivery in experimental heart failure.

Mariani JA, Smolic A, Preovolos A, Byrne MJ, Power JM, Kaye DM.

Eur J Heart Fail. 2011 Mar;13(3):247-53. doi: 10.1093/eurjhf/hfq234. Epub 2011 Feb 2.

13.

Heart failure-inducible gene therapy targeting protein phosphatase 1 prevents progressive left ventricular remodeling.

Miyazaki Y, Ikeda Y, Shiraishi K, Fujimoto SN, Aoyama H, Yoshimura K, Inui M, Hoshijima M, Kasahara H, Aoki H, Matsuzaki M.

PLoS One. 2012;7(4):e35875. doi: 10.1371/journal.pone.0035875. Epub 2012 Apr 27.

14.

Gene therapy for heart failure.

Greenberg B.

J Cardiol. 2015 Sep;66(3):195-200. doi: 10.1016/j.jjcc.2015.02.006. Epub 2015 Mar 25. Review.

15.

Design of a phase 2b trial of intracoronary administration of AAV1/SERCA2a in patients with advanced heart failure: the CUPID 2 trial (calcium up-regulation by percutaneous administration of gene therapy in cardiac disease phase 2b).

Greenberg B, Yaroshinsky A, Zsebo KM, Butler J, Felker GM, Voors AA, Rudy JJ, Wagner K, Hajjar RJ.

JACC Heart Fail. 2014 Feb;2(1):84-92. doi: 10.1016/j.jchf.2013.09.008. Epub 2014 Jan 25.

PMID:
24622121
16.

Urocortin 2 inhibits furosemide-induced activation of renin and enhances renal function and diuretic responsiveness in experimental heart failure.

Rademaker MT, Charles CJ, Nicholls MG, Richards AM.

Circ Heart Fail. 2009 Nov;2(6):532-40. doi: 10.1161/CIRCHEARTFAILURE.109.861336. Epub 2009 Sep 22.

17.

Long-term effects of AAV1/SERCA2a gene transfer in patients with severe heart failure: analysis of recurrent cardiovascular events and mortality.

Zsebo K, Yaroshinsky A, Rudy JJ, Wagner K, Greenberg B, Jessup M, Hajjar RJ.

Circ Res. 2014 Jan 3;114(1):101-8. doi: 10.1161/CIRCRESAHA.113.302421. Epub 2013 Sep 24.

18.

Integrated hemodynamic, hormonal, and renal actions of urocortin 2 in normal and paced sheep: beneficial effects in heart failure.

Rademaker MT, Cameron VA, Charles CJ, Richards AM.

Circulation. 2005 Dec 6;112(23):3624-32.

19.

Robust adenoviral and adeno-associated viral gene transfer to the in vivo murine heart: application to study of phospholamban physiology.

Champion HC, Georgakopoulos D, Haldar S, Wang L, Wang Y, Kass DA.

Circulation. 2003 Dec 2;108(22):2790-7. Epub 2003 Nov 24.

20.

Concomitant intravenous nitroglycerin with intracoronary delivery of AAV1.SERCA2a enhances gene transfer in porcine hearts.

Karakikes I, Hadri L, Rapti K, Ladage D, Ishikawa K, Tilemann L, Yi GH, Morel C, Gwathmey JK, Zsebo K, Weber T, Kawase Y, Hajjar RJ.

Mol Ther. 2012 Mar;20(3):565-71. doi: 10.1038/mt.2011.268. Epub 2012 Jan 3.

Supplemental Content

Support Center